StocksMedium•14 October 2026•
1 min read
Eton and Aquestive Sign Exclusive U.S. Licensing Deal for Epilepsy Treatment LIBERVANT
Key Facts
1Eton Pharmaceuticals and Aquestive Therapeutics entered into an exclusive U.S. license and supply agreement for LIBERVANT buccal film.
2Eton anticipates commercial availability of LIBERVANT in April 2027, subject to final U.S. FDA approval.
Eton Pharmaceuticals and Aquestive Therapeutics entered into an exclusive U.S. license and supply agreement for LIBERVANT buccal film. Reuters reported that Eton anticipates commercial availability of the product in April 2027, subject to final approval from the U.S. Food and Drug Administration (FDA).
ETON closed at $53.33 on October 13, 2026, while AQST closed at $4.67 on the same date. The agreement allows Eton to expand its rare disease portfolio, while Aquestive leverages Eton's commercial infrastructure for its Orphan Drug-designated delivery technology.